HRAS and lung carcinoma: The BioCarta RAS signature, the HRAS signature, and the KRAS signature were tested for their diagnostic capabilities in human lung cancer using a gene expression dataset with 45 adenocarcinoma lung cancer samples and 48 squamous lung cancer samples [25].